David Chiswell

Chiswell, 65, was head of one of Britain’s most successful life sciences companies, Cambridge Antibody Technology. He went on to found and chair Kymab, which develops drugs with the help of mice genetically engineered to produce human antibodies. He is now adviser to the firm, which has had $100m of investment from backers such as Shenzhen Hepalink Pharmaceutical.